We further observed that combinations of CG-806 with the Bcl-2 antagonist venetoclax and/or the Mcl-1 inhibitor A1210477 had synergistic pro-apoptotic effects not only in FLT3-mutated AML cells (both those with FLT3-ITD mutations and those with FLT3-ITD + “gatekeeper” F691 mutations), but also in FLT3-WT cells, indicating that the combinatorial regimens may have a promising anti-leukemia efficacy in both FLT3-WT and mutant AML. This evidence concerns the gene MCL1 and acute myeloid leukemia.